Vertex Pharmaceuticals, Inc.

Alios Biopharma, Inc.

Spero Trinem, Inc.

Anuj K Kuldipkumar

Ales Medek

Michael Waldo

Young Chun Jung

Praveen Mudunuri

Lori Ann Ferris

William Aloysius Nugent

David Richard Willcox

Mariusz Krawiec

Dean Shannon

Brian Luisi

David J Lauffer

Pan Li

Yi Shi

Stefanie Roeper

Shereen Ibrahim

David B Miller, Jr

The present application relates to solid state forms, for example, crystalline forms of 2'-C-methyluridine-5&#x2032;-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, pharmaceutical compositions that can include one or more solid forms of 2&#x2032;-C-methyluridine-5&#x2032;-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, and methods of treating or ameliorating diseases and/or conditions with one or more solid forms of 2&#x2032;-C-methyluridine-5&#x2032;-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate. Also disclosed herein are methods of treating diseases and/or conditions with one or more solid forms of 2&#x2032;-C-methyluridine-5&#x2032;-(O-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate in combination with one or more other agents.

Solid forms of a thiophosphoramidate nucleotide prodrug

The present application relates to solid state forms, for example, crystalline forms of 2'-C-methyluridine-5&#x2032;-(O-phenyl-N&#x2014;(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, pharmaceutical compositions that can include one or more solid forms of 2&#x2032;-C-methyluridine-5&#x2032;-(O-phenyl-N&#x2014;(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, and methods of treating or ameliorating diseases and/or conditions with one or more solid forms of 2&#x2032;-C-methyluridine-5&#x2032;-(O-phenyl-N&#x2014;(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate. Also disclosed herein are methods of treating diseases and/or conditions with one or more solid forms of 2&#x2032;-C-methyluridine-5&#x2032;-(O-phenyl-N&#x2014;(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate in combination with one or more other agents.

The present application is directed to solid forms of compounds of formula I: and pharmaceutically acceptable salts thereof, that inhibit bacterial gyrase and/or Topo IV and pharmaceutical compositions comprising said compounds and salts. These compounds and salts are useful in treating bacterial infections.

Solid forms of gyrase inhibitor (R)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pryimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1H-benzimidazol-2-yl]urea

Solid forms of gyrase inhibitor (R)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1H-benzimidazol-2-yl]urea

The present invention relates to anhydrous and hydrated forms of Compound 1, which are useful in the inhibition of c-Met protein kinase. The invention also provides pharmaceutically acceptable compositions comprising compounds of formula I and methods of using the compositions in the treatment of proliferative disorders. 

Aminopyrazole triazolothiadiazole inhibitor of c-Met protein kinase

Growing community of inventors

Medford, MA, United States of America

Anuj K Kuldipkumar